Clomiphene citrate induces ovulation by blocking estrogen receptors in the hypothalamus. Normally, circulating estradiol provides negative feedback that suppresses gonadotropin-releasing hormone pulsatility and keeps follicle-stimulating hormone low. Clomiphene occupies hypothalamic estrogen receptor alpha and prevents this feedback signal, creating a perceived estrogen-deficient state. The hypothalamic-pituitary axis responds by increasing follicle-stimulating hormone secretion, which recruits and drives follicular development in women with intact axis function — typically women with anovulation due to polycystic ovary syndrome.

The pharmacological paradox of clomiphene is that the same estrogen receptor blockade that restores follicle-stimulating hormone simultaneously impairs the uterine and cervical environment. The endometrium becomes thin and poorly proliferating; cervical mucus becomes viscous and impenetrable. These anti-estrogenic peripheral effects explain why ovulation rates with clomiphene are high but live birth rates per cycle are substantially lower — the treatment restores the egg but damages the path to implantation.

Letrozole is an aromatase inhibitor that reduces estrogen production by blocking conversion of androgens to estrogens in ovarian granulosa cells. The resulting transient drop in estradiol removes negative feedback from the hypothalamic-pituitary axis — the same net result as clomiphene but by a different route: inhibiting synthesis rather than blocking the receptor.

The critical advantage is that letrozole leaves estrogen receptors throughout the body free to respond to whatever estradiol the developing follicle produces. As the follicle grows and begins secreting estradiol, that estradiol can act normally on the endometrium (producing good proliferation) and on cervical mucus (maintaining permeability). By the time significant follicular estradiol production begins, letrozole has been cleared from the body — its half-life is short — so it does not interfere with these downstream effects. The result is a more physiological reproductive environment, a higher live birth rate than clomiphene, and a lower rate of multiple gestation because the intact negative feedback loop limits excessive follicular recruitment.

Letrozole is now the preferred first-line ovulation induction agent for women with polycystic ovary syndrome. It is used off-label for this indication in the United States but is the standard of care per guidelines from the American Society for Reproductive Medicine.

Human chorionic gonadotropin is structurally homologous to luteinizing hormone — both share an identical alpha subunit and closely related beta subunits — and binds the luteinizing hormone receptor with high affinity. This cross-reactivity is the basis for using human chorionic gonadotropin as an injection to replicate the mid-cycle luteinizing hormone surge in ovulation induction and assisted reproduction cycles, where endogenous gonadotropin stimulation has suppressed spontaneous ovulation. A trigger injection of human chorionic gonadotropin causes follicular rupture approximately 34 to 36 hours later, establishing the timing for intercourse or oocyte retrieval.

The pharmacologically important difference between human chorionic gonadotropin and native luteinizing hormone is duration of action. The luteinizing hormone half-life is approximately 60 minutes; human chorionic gonadotropin persists for 24 to 36 hours, producing sustained luteinizing hormone receptor stimulation for 5 to 7 days after injection. This prolonged activity is what makes human chorionic gonadotropin useful — but also what makes it the principal driver of ovarian hyperstimulation syndrome.

In assisted reproduction cycles, concurrent use of gonadotropin-releasing hormone agonists or antagonists for pituitary suppression impairs endogenous luteinizing hormone secretion in the post-retrieval luteal phase. Without luteinizing hormone, the multiple corpora lutea cannot sustain adequate progesterone production, and the endometrium is insufficient for implantation. Progesterone supplementation is therefore mandatory in all fresh embryo transfer cycles, continued from embryo transfer until a positive pregnancy test and typically to 8 to 12 weeks of gestation if pregnancy is confirmed.

In antagonist-protocol cycles, a gonadotropin-releasing hormone agonist can be substituted for human chorionic gonadotropin as the ovulation trigger. The agonist stimulates a brief endogenous luteinizing hormone surge from the pituitary (which remains responsive because antagonists have not caused downregulation). This endogenous surge is much shorter in duration than exogenous human chorionic gonadotropin, dramatically reducing sustained luteinizing hormone receptor stimulation of the multiple corpora lutea and eliminating severe ovarian hyperstimulation syndrome in virtually all high-risk patients. The trade-off is an inadequate luteal phase, which requires either intensive luteal support or — preferably in high-risk patients — a freeze-all strategy: all embryos are vitrified and transferred in a subsequent cycle without fresh stimulation.

Ovarian hyperstimulation syndrome is an iatrogenic complication of ovarian stimulation caused by supraphysiological vascular endothelial growth factor production from multiple stimulated corpora lutea and large pre-ovulatory follicles. Vascular endothelial growth factor binds receptors on peritoneal and ovarian capillary endothelium, dramatically increasing vascular permeability. Protein-rich plasma leaks out of capillaries into the peritoneal cavity (ascites) and other third spaces, reducing intravascular volume while fluid accumulates outside vessels. The result is simultaneous third-space fluid overload and intravascular hypovolemia — hemoconcentration, reduced urine output, and in severe cases, thromboembolism and organ impairment.

Human chorionic gonadotropin drives ovarian hyperstimulation syndrome by providing sustained luteinizing hormone receptor stimulation to multiple corpora lutea simultaneously, amplifying vascular endothelial growth factor secretion far beyond what a natural luteinizing hormone surge on a single corpus luteum would produce. The prolonged half-life of human chorionic gonadotropin (versus the short-lived endogenous luteinizing hormone) sustains this stimulus for days. This is why the exogenous trigger injection can cause early-onset ovarian hyperstimulation syndrome beginning within 3 to 9 days of injection.

Late-onset ovarian hyperstimulation syndrome begins approximately 10 or more days after the trigger, driven by rising endogenous human chorionic gonadotropin from an implanting embryo. Late-onset ovarian hyperstimulation syndrome is typically more severe and more prolonged than early onset because the human chorionic gonadotropin stimulus is continuous and rising throughout the first trimester. The freeze-all strategy prevents late-onset ovarian hyperstimulation syndrome entirely.

High ovarian reserve (elevated anti-Mullerian hormone, high antral follicle count), polycystic ovary syndrome, prior history of ovarian hyperstimulation syndrome, young age, and low body weight all identify women at higher risk. A previous episode of ovarian hyperstimulation syndrome is the strongest historical predictor and mandates proactive protocol modification in subsequent cycles.